Abstract: Anionic polyelectrolytes are used as binding agents to reduce the solubility of cationic antimicrobial polyelectrolytes. Ionic attraction between the anionic stabilizing polyelectrolytes and the antimicrobial cationic polyelectrolytes results in formation of a polyelectrolyte complex (PEC). A treatment liquid comprising a stable colloid, suspension, dispersion, solution, coacervate, or emulsion of the PEC in an aqueous carrier is used to treat an article, thus coating, infiltrating, or infusing the PEC onto or into the article. Subsequent drying results in an antimicrobial article wherein the PEC is bound to the article and is significantly less prone, relative to either of the component polyelectrolytes, to being washed, leached, leaked, extracted, or migrated from the antimicrobial article during use, or when exposed to aqueous fluids or solvents.

Abstract: Provided is a method of stimulating collagen synthesis and proteoglycan (lumican and keratocan) accumulation. Collagenase isolated keratocytes were cultured with or without insulin with or without ascorbate. Insulin stimulates the synthesis of collagen but does not affect the accumulation of lumican and keratocan. Insulin plus ascorbate, however, stimulates the synthesis of collagen and increased the accumulation of these proteoglycans. The accumulation of PGDS, a KSPG that does not interact with collagen, is not affected by ascorbate. Only the collagen made in the presence of ascorbate was pepsin resistant. EDB overrode the effects of ascorbate on pepsin resistance and proteoglycan accumulation.

Abstract: A method and composition for treating healed wounds including hypertrophic scars so as to prevent scarring or reduce the size and improve the appearance of scars comprises applying to the healed wound or scar a composition comprising a fluid, film-forming carrier which may contain one or more active topical ingredients, the carrier hardening to a solid, tangible, membrane juxtaposed to the skin. Novel compositions using the film-forming carrier are also useful to treat a variety of adverse skin disorders, and internal physiological conditions.

Abstract: The present disclosure relates to anhydrous compositions for making up or caring for the skin, for example foundations, comprising at least one liquid organic phase comprising at least one non-volatile oil, at least one amorphous gelling polymer formed by polymerization of an olefin, and poly(methyl methacrylate) particles, wherein the amount of the at least one non-volatile oil present in the composition is greater than the amount of poly(methyl methacrylate) particles present in the composition. The compositions may exhibit a smooth and melting creamy texture, spread easily over the skin, and make it possible to obtain a homogeneous make-up that has a powdery and matt finish and that confers a pleasant softness on the skin. The make-up may also exhibit good properties of hold.

Abstract: Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelial tissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compositions and foamable drug delivery systems are particularly useful for the dermatological administration of corticosteroids and antifungal agents.

Abstract: The invention relates to freeze-dried compositions comprising a) at least one polymer based on polyacrylic acids and salts thereof, b) at least one natural polymer, c) optionally at least one further polymer which differs from a) and b) and d) optionally one or more active compounds and/or auxiliary substances. The invention furthermore relates to a process for the preparation of such freeze-dried compositions, the combination of such freeze-dried compositions in kit-of-parts arrangements together with aqueous solutions and the use of the freeze-dried compositions and of the kit-of-parts combinations for cosmetic and pharmaceutical use, in particular for use as a cosmetic mask or as a wound covering and for the preparation of pharmaceutical agents for treatment of dermal wounds, such as, in particular, chronic wounds, ulcus cruris or decubitus.

Abstract: The present disclosure provides gel compositions useful for treating the skin. The gel compositions are hydrogels that include from about 33 wt % to about 68 wt % of a humectant or a mixture of humectants; about 0 wt % to about 8 wt % of an electrolyte or mixture of electrolytes; from about 2 wt % to about 20 wt % of water; from about 18 wt % to about 45 wt % of a copolymer. The copolymer includes, in polymerized form, from about 80 mol % to about 95 mol % of a first monomer, which is a mixture of acrylic acid and a salt thereof, from about 5 mol % to 20 mol % of a second monomer, which can be a salt of 2-acrylamido-2-methylpropane sulfonic acid, and, optionally a crosslinking agent. In embodiments, the gel composition has a pH of about 7.0 or less. The dermal patches of the present disclosure may be utilized in skin care, and may include the application of the patch, its removal, and re-application to tissue.

Abstract: Absorbable polyurethanes, polyamides and polyester urethanes prepared from at least one compound selected from: or the diamines and diisocyanates thereof, wherein each X represents a member independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO— where y is one of the numbers 2, 3, 4 or 6-24 inclusive, and —(CH2CH2O)z?CH2COO— where z? is an integer between 2 and 24, inclusive; each Y represents a member independently selected from —COCH2O— (glycolic ester moiety), —COCH(CH3)O— (lactic ester moiety), —COCH2OCH2CH2O— (dioxanone ester), —COCH2CH2CH2CH2CH2O— (caprolactone ester), —CO(CH2)mO— where m is an integer between 2, 3, 4 or 6-24 inclusive, —COCH2O(CH2CH2O)n— where n is an integer between 2 and 24, inclusive; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; p is an integer between 1 and 4, inclusive; and Rn represents one or more

Abstract: Compositions and methods for treating angiogenesis-related diseases and for skin care in mammals is disclosed that includes, as an active pharmaceutical agent, an effective amount of purified extract from Angelica sinensis, or a fraction or a lyophilizate thereof, or one or more active component contained in said extract.

Abstract: Hemostatic wound dressings that include cationic polymers and related hydrogels, methods for making and using the wound dressings.

Abstract: The liquid, polymer-containing coating materials of this invention comprise a polymer of a polymerizable, nitrogen-containing, hydrophilic monomer, which may give thermoresponsive properties, and which is copolymerized with a hydrophobic, polymerizable siloxy-containing monomer, in a solvent system of a volatile hydrophobic (non-polar) liquid that is non-stinging to a user. The material forms a coating or bandage in the form of a film when applied to a surface or the skin of a user.

Abstract: A composition and method of arresting the flow of blood from a bleeding wound. The composition preferably includes an anhydrous salt ferrate compound preferably combined with an effective amount of an insoluble cation exchange material and an effective amount of anhydrous Magnetite mixed uniformly together. Povidone iodine may be added for enhanced antimicrobial properties. In the method, a quantity of the composition is magnetically attached to a surface of a magnet, after which the powderous mixture is applied to the wound by pressing the surface covered with the powderous compound against the wound for a time sufficient to clot the blood to arrest substantial further blood flow from the wound.

Abstract: The disclosure relates to biocompatible components useful for forming compositions for use as medical/surgical synthetic adhesives and sealants. Biocompatible components of the present disclosure may include a polymeric polyol core, which may be treated with a nitroaryl compound to form a nitro ester. The resulting nitro ester groups may be reduced to form amino groups which, in turn, may be treated to form isocyanate groups. The resulting isocyanate may then be reacted with a second component to form adhesive and/or sealant compositions.

Abstract: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.

Abstract: The invention provides a method of modulating proteases, particularly when treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The medium containing the proteases (e.g. the wound) is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule.

Abstract: The invention provides a dressing composition comprising a bisphosphonate matrix metalloproteinase (MMP) inhibitor covalently bound to a polymer wherein, when the dressing is contacted with a wound, substantially all of the bisphosphonate remains with the dressing composition and is unable to enter the wound tissue. The invention also provides for a method of treatment of a wound by contacting a dressing composition comprising a covalently bound MMP inhibitor with the wound fluid to thereby selectively inhibit one or more MMP's in the wound fluid without inhibiting those in the wound tissue.

Abstract: A novel macromer or mixture thereof is described herein, comprising isocyanatophenyl ether terminal moieties and at least two residues of a water-soluble polymer having a molecular weight ranging from 80 to 10,000 adjacent to the ether group of the isocyanatophenyl ether terminal isocyanate moieties, thereby forming at least two ether linkages in the macromer or mixture thereof. A method for making a polyisocyanate macromer is also described herein.

Abstract: A method and composition for treating healed wounds including hypertrophic scars so as to prevent scarring or reduce the size and improve the appearance of scars comprises applying to the healed wound or scar a composition comprising a fluid, film-forming carrier which may contain one or more active topical ingredients, the carrier hardening to a solid, tangible, membrane juxtaposed to the skin. Novel compositions using the film-forming carrier are also useful to treat a variety of adverse skin disorders, and internal physiological conditions.

Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Abstract: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic swelling and/or neurogenic inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic swelling and/or neurogenic inflammation.

Abstract: The present invention provides a method for treating symptoms of diabetes in a diabetic subject which comprises administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts so as to treat chronic symptoms of diabetes in the subject.

Abstract: Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed.

Abstract: A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

Abstract: A composition for treating wounds of the skin, such as those caused by the bites of small insects or jellyfish, includes a wax or resin, an emulsifier, and ammonium hydroxide. The composition is applied to the skin in a thin layer, and when it dries, it forms a thin, protective film over the wound. Application of the composition has been found to provide temporary and immediate relief of pain and/or itching. The protective film shields the wound, and therefore aids in healing. The composition can be made of any of a variety of waxes or resins, and the emulsion can be formed with long-chain alcohol or fatty acid soaps, such as oleic acid or triethanolamine.

Abstract: Bioabsorbable compounds which include a polyalkylene oxide backbone with two or more isocyanate substituents are useful as one component adhesives. Absorbable compositions useful as a two component adhesive contain a) a polyethylene oxide having two or more amine substituents with b) a bioabsorbable diisocyanate compound, or alternatively contain a) a polyethylene oxide having two or more isocyanate substituents with b) a bioabsorbable diamine compound, or, alternatively contain a) a bioabsorbable diisocyanate compound and b) a bioabsorbable diamine compound.

Abstract: The present invention describes microbicidal hydrophilic polyurethane foams endowed with polyhexamethylenebiguanide (PHMB) and/or its hydrochloride and also a superabsorbent, wound contact materials obtainable therefrom and processes for producing the therapeutically endowed polyurethane foams and the wound contact materials obtainable therefrom.

Abstract: The present invention relates to a composition for repairing injured skin containing a saccharide and povidone-iodine. The present invention has the following characteristics: suppresses time-dependent increase of consistency, it is easy to use, it is a soft preparation, and has superior applicability to a deep wounded lesion and a granulation tissue. The composition of the present invention contains 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid.

Abstract: The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field.

Abstract: A polymerizable antimicrobial formulation for forming a wound closure adhesive comprising cyanoacrylate monomer, diiodomethyl-p-tolylsulfone and a halogenated hydroxyl diphenyl ether; and a method for closing the approximated edges of a wound with a polymeric film that substantially inhibits the growth of microorganisms, where the polymeric film is formed by use of the polymerizable antimicrobial formulation.

Abstract: The present invention provides a substrate having a plurality of immobilised furanone moieties associated with at least part of a surface of the substrate. The invention also relates to articles consisting of or comprising such a substrate.

Abstract: The present invention provides a method of attenuating the formation or reducing the severity of a neurogenic bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of bruising.

Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Abstract: The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof; and a pharmaceutically acceptable excipient.

Abstract: A method of adhering biological tissue that includes applying a bio-degradable adhesive to the tissue. The adhesive includes a moisture-curable, isocyanate-functional component prepared by reacting (a) a multi-functional isocyanate component and (b) a multi-functional active hydrogen component that includes at least 30% by weight, based upon the total weight of the multi-functional active hydrogen component, of a multi-functional active hydrogen reactant having an equivalent weight less than 100. The ratio R of active hydrogen groups to isocyanate groups can be less than 1.0.

Abstract: A method for treating wounds by adhering a wound dressing to a wound with a polymerizable alkyl cyanoacrylate composition, such that the wound dressing and cyanoacrylate composition seal the wound to inhibit bleeding and infection. The dressing may be in the form of a mitten. Also disclosed is injection of polymerizable cyanoacrylate into puncture wounds to seal the wounds and inhibit bleeding.

Abstract: A method of making a wound dressing comprises dissolving at least one hemostatic agent in at least one solvent to form a solution. The method continues by freeze drying the solution to form a sponge. The method further comprises compressing the sponge, wherein the sponge is subjected to a vapor above ambient temperature prior to or during the compression.

Abstract: Adhesive systems comprising: (A) an isocyanate group-containing prepolymer prepared by reacting: (A1) an aliphatic isocyante; and (A2) a polyol having a number average molecular weight of ?400 g/mol and 2 to 6 OH groups; and (B) a curing component comprising: (B1) an amino group-containing aspartate ester of the general formula (I); wherein X represents an n-valent organic radical derived from a corresponding n-functional primary amine X(NH2)n, R1 and R2 each independently represent an organic radical having no Zerevitinov active hydrogens and n represents a whole number of at least 2; and (B2) an organic filler having a viscosity of 10 to 6000 mPas at 23° C. measured according to DIN 53019; their use in wound and tissue incision closure, adhesive films comprising the same and dispensing systems therefor.

Abstract: Compositions for use in the treatment of wounds and fibrosis comprising a therapeutically effective amount of a compound that modulates actin assembly and organization intracellularly and/or extracellularly and a pharmaceutically acceptable vehicle; such a compound promotes the rate of wound healing and also prevents or reduces fibrosis. A preferred compound is gelsolin.

Abstract: The invention provides a method of treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The wound is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule.

Abstract: There is provided a treatment product (1) comprising a patch (3), said patch (3) comprising a polysiloxane as a treatment agent, and wherein the patch (3) is arranged such that it can be removeably adhered to a user's skin. Also provided are other treatment products, the use of polysiloxane for manufacturing a medicament and the use of polysiloxane to treat a cutaneous condition.

Abstract: A novel composition for use in treating a wound, burn or other skin condition comprises one or more compounds of formula (I), wherein: m = 0-6, n = 6-100, Q, R and R? may be independently selected from, C1-5 alkyl, OU, UOCH2CH3, CH2CH3, UOCH3, OH, O(CH2)y(OU)yCH3, (OCH2CH2)yOU, (OCH2CH2)yOH, UOH, UOU?, UCO2U?, CO2U, UCO2COU, CO2H, UCO2H, COX, UCOX, UCO2 R?, CO2COU, Aryl, ArylU, ArylUU, ArylUU?U?, NH2, UNH2, NHU, NUU?, NO2, UNO2, UCONH2, CONH2, UCONHU?, CONHU, UCONU?U?, CONU?U?, halogen, PO4H3, PO4H3-z, PO4H3-zU (z = 0, 1, 2 or 3), PU3, P U?U?U??SH, SO2 and SO3H; wherein U, U?, U? and U?? may be independently selected from any alkyl, alkenyl or alkynyl group where the number of carbon atoms is between 1 and 31; wherein X=halogen; wherein y=1-100; provided that Q, R and R? can not all be C1 alkyl; and wherein the compound of formula (I) is present in an amount of at least 1% of the composition.

Abstract: Described herein is a physiologically-balanced, acidic solution. Typically the solution is prepared by a chemical reactions or by the electrolysis of a solution comprising a mixture of an inorganic salt to form a physiologically balanced solution. This invention also relates to methods for use of the solutions, including a specialized bandage which may be used in combination with the solutions, or optionally with other topically applied materials. A mixture of inorganic salts and, optionally minerals, is used in order to mimic the electrolyte concentration and mixture of body fluid in an isotonic state. The solution typically comprises of one halide salt of lithium, sodium, potassium, calcium, and other cations. Typically the halide is fluoride, chloride, bromide, or iodide, and most typically chloride.

Abstract: Bolus materials for use in radiation therapy methods of making such bolus material and methods of providing radiation therapy using such bolus material are provided. The bolus materials can be an oil gel that includes at least one thermoplastic elastomer and an oily substance. The bolus materials are transparent and can have a maximum strain of at least 50%, a Young's Modulus of less than about 0.1 GPa, and a hardness less than about 90 on the Shore A scale.

Abstract: A topical product for the application to the skin or mucosal surfaces comprises yellow beeswax in an oleaginous base of, e.g., olive oil, sunflower oil, almond oil, cod liver oil, castor oil, along with an excipient vehicle. The product is useful in connection with a variety of conditions and ailments of the skin (including burns and abrasions) and mucosal surfaces of, for example, the vaginal and anal areas.

Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.

Abstract: A composition is provided to heal burns, wounds and other skin traumas of mammals. The composition is useful to treat sepsis and to improve skin formation as well. The composition comprises an antimicrobial peptide having amino acid sequence FAKKFAKKFKKFAKKFAKFAFAF.

Abstract: A method of treating a non-human dermatological disorder, wherein the method comprises topically administering to a non-human dermatological disorder a therapeutically effective amount of a topical composition containing: (1) an active component comprising at least one salicylate derivative; and (2) at least one pharmaceutically acceptable solubilizer.

Abstract: Topical preparations for release of an active agent and to methods of making and using the topical preparations are provided. The preparations may have an internal phase dispersed within an external phase. The internal phase may be a hydrophilic carrier and an active agent. The external phase may be a silicone matrix.

Abstract: The present invention describes the use of polysaccharide derivatives for the preparation of biocompatible and biodegradable biomaterials with absorbent properties for body fluids and physical hemostatic activity, to be used in both venous and arterial vascular anastomoses to create a physical hemostatic barrier and to prevent scar tissue formation and formation of post-surgical adherence of the vessels to the surrounding tissues.

Abstract: Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelial tissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compositions and foamable drug delivery systems are particularly useful for the dermatological administration of corticosteroids and antifungal agents.